Evidence map›Paper›PMID 33425766›Full record

ReviewFrontiers in oncology2020

Vanessa E Kennedy, Catherine C Smith

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Quizartinib for Newly DiagnosedJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.Current hematologic malignancy reports · 2026
    Review
  12. Article
  13. Review
  14. Review
  15. 6-(2-Aminoethyl)-6Biomolecules · 2026
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vanessa E KennedyDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, United States.
Catherine C SmithDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, United States.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts. Mutations in

Indexed as

Acute Myeloid LeukemiaFLT3 inhibitorFLT3 inhibitor maintenanceFLT3 resistancenon-canonical FLT3 mutation

Identifiers

PMID33425766
PMCPMC7787101
OpenAlexW3114932971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.